#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cardiomyopathy Osteosarcoma Gastrointestinal neuroendocrine tumour Cholangiocarcinoma Adrenogenital syndrome Hepatic cirrhosis Tourette's disorder Primary biliary cholangitis Neoplasm Retinitis pigmentosa Rett syndrome Ornithine transcarbamoylase deficiency Osteogenesis imperfecta Peripheral T-cell lymphoma unspecified Neuropathic arthropathy More trials…

    Learn about Rare Diseases

    Rhabdomyosarcoma – Treatment Langerhans cell sarcoma – Diagnostics Mantle cell lymphoma stage IV – Diagnostics CADASIL – Trials in Disease Alport’s syndrome – Diagnostics Haemophilia B without inhibitors – Diagnostics Von Willebrand’s disease – Life with Disease Congenital nephrogenic diabetes insipidus – Treatment Biotinidase deficiency – Diagnostics Turner’s syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Amlodipine Besilate LY3841136 SODIUM Indometacin Calcium Carbonate Propafenone Hydrochloride Fluorodopa (18F) Pimecrolimus Specific Nucleic Acid Sna-Xfsa BUDOPRUTUG Ampreloxetine Alx148 Izokibep Hhalpc OXYBUTYNIN HYDROCHLORIDE ALLERGEN EXTRACTS Capmatinib JNJ-75276617 Mometasone Furoate Cendakimab Orismilast More therapies…

    Learn about Your Condition

    Hairy cell leukaemia recurrent Subdural haematoma Diverticulitis Deafness traumatic T-cell lymphoma Intracranial calcification Breast cancer female Neonatal asphyxia Coronary artery bypass Craniotomy Eosinophilic gastritis Colonoscopy Allergic respiratory disease Psychotic behaviour Carpal tunnel syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Nagyerdei Korut 98, Debrecen, 4032, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

    Recruiting

    3 1 1
    Investigated Diseases:
    • Gastrointestinal stromal tumour
    Investigated Drugs:
    • Imatinib Mesilate
    • [4-(METHYL-1H-PYRAZOL-4-YL)-BENZYL]-(6[7-(3-PYRROLIDIN-1-YL-PROPOXY)-IMIDAZO[1,2-A]PYRIDIN-3-YL]-PYRIMIDIN-4-YL]-AMINE
    Finland France Germany Greece Hungary Italy +7

  • Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

    Recruiting

    2 1 1
    Investigated Drugs:
    • Human Normal Immunoglobulin (Iv)
    • Tocilizumab
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    France Greece Hungary Portugal Spain Sweden

  • Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    Austria Belgium Czechia Denmark Finland France +6

  • Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Sodium Chloride
    Bulgaria Czechia Germany Hungary Poland Spain

  • A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

    Recruiting

    3 1
    Investigated Diseases:
    • Polycythaemia vera
    Investigated Drugs:
    • Sapablursen
    Austria Czechia France Germany Hungary Italy +3

  • Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

    Recruiting

    3 1 1
    Investigated Drugs:
    • Aflibercept
    Czechia Hungary Latvia Lithuania Poland Slovakia +1

  • Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

    Recruiting

    2 1
    Bulgaria Denmark France Germany Greece Hungary +4

  • A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Azd5004
    • Dapagliflozin
    Czechia Denmark Germany Greece Hungary Poland +1

  • A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

    Recruiting

    3 1
    Investigated Drugs:
    • 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
    • Bi 1015550
    Austria Belgium Bulgaria Croatia Czechia Denmark +15

  • Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

    Recruiting

    4 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • LUNSEKIMIG
    Belgium Denmark Estonia Finland France Germany +7
1 2 3 … 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!